Twist Bioscience on Track for Highest Close Since 2021 on Work with Anthropic

Dow Jones08-20 00:31

Shares of Twist Bioscience gained after Anthropic said it chose the company as one of its independent evaluators to test if Claude can help accelerate parts of the drug design process.

The stock climbed 17% to $136.41 on Wednesday, on track for its highest close since 2021. The stock has more than quadrupled year to date.

Anthropic said it is using Twist's help to determine whether its Claude artificial-intelligence model can design minibinders--small proteins designed to latch onto a target protein--for multiple protein targets.

The AI company conducted a multi-arm protein design campaign against 15 targets. Twist Bioscience and Adaptyv Bio, another evaluator checking Claude's work, independently produced and tested Claude's designs in the lab. They found that, of the 15 targets Anthropic designed against, Claude successfully designed binders against 14 of them.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660537422?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 00:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660537422","market":"sh","top_or_hot":-1,"title":"Twist Bioscience on Track for Highest Close Since 2021 on Work with Anthropic","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/TWST\">Twist Bioscience</a> gained after Anthropic said it chose the company as one of its independent evaluators to test if Claude can help accelerate parts of the drug design process. \n</p>\n<p>\n  The stock climbed 17% to $136.41 on Wednesday, on track for its highest close since 2021. The stock has more than quadrupled year to date. \n</p>\n<p>\n  Anthropic said it is using Twist's help to determine whether its Claude artificial-intelligence model can design minibinders--small proteins designed to latch onto a target protein--for multiple protein targets. \n</p>\n<p>\n  The AI company conducted a multi-arm protein design campaign against 15 targets. Twist Bioscience and Adaptyv Bio, another evaluator checking Claude's work, independently produced and tested Claude's designs in the lab. They found that, of the 15 targets Anthropic designed against, Claude successfully designed binders against 14 of them. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Twist Bioscience on Track for Highest Close Since 2021 on Work with Anthropic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTwist Bioscience on Track for Highest Close Since 2021 on Work with Anthropic\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-08-20 00:31</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/TWST\">Twist Bioscience</a> gained after Anthropic said it chose the company as one of its independent evaluators to test if Claude can help accelerate parts of the drug design process. \n</p>\n<p>\n  The stock climbed 17% to $136.41 on Wednesday, on track for its highest close since 2021. The stock has more than quadrupled year to date. \n</p>\n<p>\n  Anthropic said it is using Twist's help to determine whether its Claude artificial-intelligence model can design minibinders--small proteins designed to latch onto a target protein--for multiple protein targets. \n</p>\n<p>\n  The AI company conducted a multi-arm protein design campaign against 15 targets. Twist Bioscience and Adaptyv Bio, another evaluator checking Claude's work, independently produced and tested Claude's designs in the lab. They found that, of the 15 targets Anthropic designed against, Claude successfully designed binders against 14 of them. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2660537422","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660537422","pubTimestamp":1787157060,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Twist Bioscience gained after Anthropic said it chose the company as one of its independent evaluators to test if Claude can help accelerate parts of the drug design process.The stock climbed 17% to $136.41 on Wednesday, on track for its highest close since 2021. The stock has more than quadrupled year to date.Anthropic said it is using Twist's help to determine whether its Claude artificial-intelligence model can design minibinders--small proteins designed to latch onto a target protein--for multiple protein targets.The AI company conducted a multi-arm protein design campaign against 15 targets. Twist Bioscience and Adaptyv Bio, another evaluator checking Claude's work, independently produced and tested Claude's designs in the lab. They found that, of the 15 targets Anthropic designed against, Claude successfully designed binders against 14 of them.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","IDNA":"iShares Genomics Immunology and Healthcare ETF","BK4139":"生物科技","WDNA":"WisdomTree BioRevolution Fund","TWST":"Twist Bioscience Corp","GNOM":"Global X Genomics & Biotechnology ETF","BK4588":"碎股","ARKG":"ARK Genomic Revolution ETF"},"translate_title":"Twist Bioscience 与 Anthropic 的合作有望实现 2021 年以来的最高接近","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GNOM":0.6,"ARKG":0.6,"TWST":0.9,"WDNA":0.6,"IDNA":0.6},"content_text":"Shares of Twist Bioscience gained after Anthropic said it chose the company as one of its independent evaluators to test if Claude can help accelerate parts of the drug design process. \n\n\n  The stock climbed 17% to $136.41 on Wednesday, on track for its highest close since 2021. The stock has more than quadrupled year to date. \n\n\n  Anthropic said it is using Twist's help to determine whether its Claude artificial-intelligence model can design minibinders--small proteins designed to latch onto a target protein--for multiple protein targets. \n\n\n  The AI company conducted a multi-arm protein design campaign against 15 targets. Twist Bioscience and Adaptyv Bio, another evaluator checking Claude's work, independently produced and tested Claude's designs in the lab. They found that, of the 15 targets Anthropic designed against, Claude successfully designed binders against 14 of them.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660537422","isCrawlerRequest":true}